132 related articles for article (PubMed ID: 17936175)
61. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients.
Cervera R; Khamashta MA; Shoenfeld Y; Camps MT; Jacobsen S; Kiss E; Zeher MM; Tincani A; Kontopoulou-Griva I; Galeazzi M; Bellisai F; Meroni PL; Derksen RH; de Groot PG; Gromnica-Ihle E; Baleva M; Mosca M; Bombardieri S; Houssiau F; Gris JC; Quéré I; Hachulla E; Vasconcelos C; Roch B; Fernández-Nebro A; Piette JC; Espinosa G; Bucciarelli S; Pisoni CN; Bertolaccini ML; Boffa MC; Hughes GR;
Ann Rheum Dis; 2009 Sep; 68(9):1428-32. PubMed ID: 18801761
[TBL] [Abstract][Full Text] [Related]
62. [Dermatological manifestations in the antiphospholipid syndrome].
Twig G; Sherer Y; Shoenfeld Y
Harefuah; 2005 Sep; 144(9):639-41, 675. PubMed ID: 16218536
[TBL] [Abstract][Full Text] [Related]
63. How to manage patients with systemic lupus erythematosus who are also antiphospholipid antibody positive.
Giles I; Rahman A
Best Pract Res Clin Rheumatol; 2009 Aug; 23(4):525-37. PubMed ID: 19591782
[TBL] [Abstract][Full Text] [Related]
64. Laboratory testing and identification of antiphospholipid antibodies and the antiphospholipid syndrome: a potpourri of problems, a compilation of possible solutions.
Favaloro EJ; Wong RC
Semin Thromb Hemost; 2008 Jun; 34(4):389-410. PubMed ID: 18814073
[TBL] [Abstract][Full Text] [Related]
65. Childhood systemic sclerosis.
Zulian F; Martini G
Curr Opin Rheumatol; 2007 Nov; 19(6):592-7. PubMed ID: 17917540
[TBL] [Abstract][Full Text] [Related]
66. Prevalence of antiphospholipid and antinuclear antibodies in children with epilepsy.
Constantin T; Kálovics T; Ponyi A; Nagy E; Sallai K; Szabó L; Garami M; Müller J; Gergely P; Dankó K; Fekete G; Kálmánchey R
Med Sci Monit; 2009 Apr; 15(4):CR164-9. PubMed ID: 19333200
[TBL] [Abstract][Full Text] [Related]
67. Ethnicity and APS.
Wilson WA
J Autoimmun; 2000 Sep; 15(2):153-5. PubMed ID: 10968902
[TBL] [Abstract][Full Text] [Related]
68. Upregulation of antiphospholipid antibodies following cyclophosphamide therapy in patients with systemic lupus erythematosus.
Vlachoyiannopoulos PG; Toya SP; Katsifis G; Zintzaras E; Tzioufas AG; Moutsopoulos HM
J Rheumatol; 2008 Sep; 35(9):1768-75. PubMed ID: 18634157
[TBL] [Abstract][Full Text] [Related]
69. Pediatric antiphospholipid syndrome.
Madison JA; Zuo Y; Knight JS
Eur J Rheumatol; 2020 Feb; 7(Suppl1):S3-S12. PubMed ID: 31804173
[TBL] [Abstract][Full Text] [Related]
70. Erratum: Clinical Delphi on aPL Negativization: Report from the APS Study Group of the Italian Society for Rheumatology (SIR-APS).
Sciascia S; Foddai SG; Alessandri C; Alunno A; Andreoli L; Barinotti A; Calligaro A; Canti V; Carubbi F; Cecchi I; Chighizola CB; Conti F; Emmi G; Fioravanti A; Fischetti F; Franceschini F; Gerosa M; Hoxha A; Larosa M; Lazzaroni MG; Nalli C; Pazzola G; Radin M; Raffeiner B; Ramoni VL; Rubini E; Sebastiani GD; Truglia S; Urban ML; Roccatello D; Tincani A
Thromb Haemost; 2022 Sep; 122(9):e1. PubMed ID: 37225134
[No Abstract] [Full Text] [Related]
71. The Pediatric Forum: No Radiograph in the Management of Pediatric Torus Fractures.
Farbman KS; Vinci RJ; Bauchner H; Cranley WR; Creevy WR
Arch Pediatr Adolesc Med; 2000 Jul; 154(7):750. PubMed ID: 10891033
[No Abstract] [Full Text] [Related]
72. Material Witnesses: APS Meeting in Cincinnati: Buckyballs: A Little Like Basketballs--Only Smaller.
Flam F
Science; 1991 Apr; 252(5002):29. PubMed ID: 17739062
[No Abstract] [Full Text] [Related]
73. Primary antiphospholipid syndrome in pediatrics: beyond thrombosis. Report of 32 cases and review of the evidence.
Torres-Jimenez AR; Ramirez-Nova V; Cespedes-Cruz AI; Sanchez-Jara B; Velazquez-Cruz A; Bekker-Méndez VC; Guerra-Castillo FX
Pediatr Rheumatol Online J; 2022 Feb; 20(1):13. PubMed ID: 35164787
[TBL] [Abstract][Full Text] [Related]
74. Non-Criteria Manifestations of Juvenile Antiphospholipid Syndrome.
Miyamae T; Kawabe T
J Clin Med; 2021 Mar; 10(6):. PubMed ID: 33802787
[TBL] [Abstract][Full Text] [Related]
75. Pediatric antiphospholipid syndrome.
Aguiar CL; Soybilgic A; Avcin T; Myones BL
Curr Rheumatol Rep; 2015 Apr; 17(4):27. PubMed ID: 25854492
[TBL] [Abstract][Full Text] [Related]
76. Reviewing the recommendations for lupus in children.
Arıcı ZS; Batu ED; Ozen S
Curr Rheumatol Rep; 2015 Mar; 17(3):17. PubMed ID: 25761924
[TBL] [Abstract][Full Text] [Related]
77. Mucocutaneous manifestations in juvenile-onset systemic lupus erythematosus: a review of literature.
Chiewchengchol D; Murphy R; Edwards SW; Beresford MW
Pediatr Rheumatol Online J; 2015; 13():1. PubMed ID: 25587243
[TBL] [Abstract][Full Text] [Related]
78. Recurrent arterial and venous thrombosis in a 16-year-old boy in the course of primary antiphospholipid syndrome despite treatment with low-molecular-weight heparin: a case report.
Biernacka-Zielinska M; Lipinska J; Szymanska-Kaluza J; Stanczyk J; Smolewska E
J Med Case Rep; 2013 Aug; 7():221. PubMed ID: 23971759
[TBL] [Abstract][Full Text] [Related]
79. Clinical and laboratory characteristics of children positive for antiphospholipid antibodies.
Giordano P; Tesse R; Lassandro G; Fracchiolla D; Ranieri P; Lotito A; De Mattia D; Del Vecchio GC
Blood Transfus; 2012 Jul; 10(3):296-301. PubMed ID: 22244004
[TBL] [Abstract][Full Text] [Related]
80. Antiphospholipid syndrome in pediatrics.
Ravelli A; Martini A
Rheum Dis Clin North Am; 2007 Aug; 33(3):499-523. PubMed ID: 17936175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
